Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Kaltenboeck

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
JAMA Health Forum|May 10, 2024
Implementing Maximum Fair Price Without Hurting PharmaciesT Joseph Mattingly, Anthony A Esterly, Anna Kaltenboeck
BMC Medical Education|July 25, 2021
The future of physician advocacy: a survey of U.S. medical studentsSusan Chimonas, Maha Mamoor, Anna Kaltenboeck, et al.
The American Journal of Managed Care|January 23, 2016
Care pathways in US healthcare settings: current successes and limitations, and future challengesAnita Chawla, Kimberly Westrich, Susanna Matter, et al.
Expert Review of Clinical Pharmacology|October 24, 2013
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copiesAnna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, et al.
The American Journal of Managed Care|May 18, 2021
Value-based management of specialty drugs: practical considerations and implications for pharmacyJason Kay, Susan Chimonas, Jennifer Ohn, et al.
MDM Policy & Practice|March 28, 2019
Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice ExperimentCamilla Somers, Susan Chimonas, Emma McIntosh, et al.
JAMA|December 5, 2023
Reimbursement to Pharmacies for Generic Drugs by Medicare Part D SponsorsInmaculada Hernandez, Nico Gabriel, Anna Kaltenboeck, et al.
Applied Health Economics and Health Policy|September 17, 2011
Early retirement and income loss in patients with early and advanced Parkinson's diseaseScott Johnson, Matthew Davis, Anna Kaltenboeck, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 14, 2013
An economic model of Parkinson's disease: implications for slowing progression in the United StatesScott J Johnson, Melissa D Diener, Anna Kaltenboeck, et al.
Health Policy (Amsterdam, Netherlands)|July 26, 2018
An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countriesSteven G Morgan, Chester B Good, Christine Leopold, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
JAMA Health Forum|May 10, 2024
Implementing Maximum Fair Price Without Hurting PharmaciesT Joseph Mattingly, Anthony A Esterly, Anna Kaltenboeck
BMC Medical Education|July 25, 2021
The future of physician advocacy: a survey of U.S. medical studentsSusan Chimonas, Maha Mamoor, Anna Kaltenboeck, et al.
The American Journal of Managed Care|January 23, 2016
Care pathways in US healthcare settings: current successes and limitations, and future challengesAnita Chawla, Kimberly Westrich, Susanna Matter, et al.
Expert Review of Clinical Pharmacology|October 24, 2013
Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copiesAnna Kaltenboeck, Genia Long, Eleanor Hayes-Larson, et al.
The American Journal of Managed Care|May 18, 2021
Value-based management of specialty drugs: practical considerations and implications for pharmacyJason Kay, Susan Chimonas, Jennifer Ohn, et al.
MDM Policy & Practice|March 28, 2019
Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice ExperimentCamilla Somers, Susan Chimonas, Emma McIntosh, et al.
JAMA|December 5, 2023
Reimbursement to Pharmacies for Generic Drugs by Medicare Part D SponsorsInmaculada Hernandez, Nico Gabriel, Anna Kaltenboeck, et al.
Applied Health Economics and Health Policy|September 17, 2011
Early retirement and income loss in patients with early and advanced Parkinson's diseaseScott Johnson, Matthew Davis, Anna Kaltenboeck, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 14, 2013
An economic model of Parkinson's disease: implications for slowing progression in the United StatesScott J Johnson, Melissa D Diener, Anna Kaltenboeck, et al.
Health Policy (Amsterdam, Netherlands)|July 26, 2018
An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countriesSteven G Morgan, Chester B Good, Christine Leopold, et al.
Pageof 4